Evolus (EOLS) vs Tilray Brands (TLRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Tilray Brands (TLRY) over the past year, gaining 23.6% versus a loss of 78.3%. Over five years, EOLS leads with a +0.9% price change compared with -96.4% for TLRY. Tilray Brands is the larger company by market cap ($549.0 million vs $511.2 million), about 1.1 times the size.
On valuation, Tilray Brands trades at a lower forward P/E (20.9x vs 26.5x for Evolus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | TLRY |
|---|---|---|
| Share price | $7.74 | $3.72 |
| Market cap | $511.23M | $549.01M |
| 1-day change | +4.88% | -1.72% |
| YTD return | +16.39% | -58.86% |
| 1-year return | +23.64% | -78.27% |
| 5-year return | +0.91% | -96.37% |
| Forward P/E | 26.46 | 20.92 |
| EPS (TTM) | $-0.56 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $23.20 |
| 52-week low | $3.86 | $3.54 |
| Distance from 52-week high | -16.86% | -83.99% |
| Analyst consensus | none | buy |
| Avg. price target upside | +93.80% | +92.73% |
| Average volume | 901.46K | 4.08M |
| Shares outstanding | 66.05M | 147.78M |
| Employees | 353 | 3,595 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed TLRY by 101.9 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
About Tilray Brands
TLRY stock →Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
Healthcare · Drug Manufacturers - Specialty & Generic · 3,595 employees
EOLS vs TLRY FAQ
Which is bigger, Evolus or Tilray Brands?
Tilray Brands (TLRY) is larger, with a market capitalization of $549.01M compared with $511.23M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or TLRY?
EOLS returned +23.64% over the past 12 months, compared with -78.27% for TLRY (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Tilray Brands in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.